FGFR1 and pancreatic neoplasm: This effect of FGFR1 blockade was also replicated when using PDAC-derived primary PSCs, PSC25 and M152 [22], PANC-1 and COLO 357 pancreatic cancer cells (Fig. 1E, Supplementary Fig. 1B–E), and with the chemically distinct FGFR inhibitor PD173074 (Supplementary Fig. 1F), demonstrating relevance across many cancer cell lines as well as CAF subtypes [9].